# Atrial Fibrillation Feasibility Certoparin Trial - AFFECT

> **NCT00171769** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 200 (—)

## Conditions studied

- Persistent Nonvalvular Atrial Fibrillation

## Interventions

- **DRUG:** Certoparin

## Key facts

- **NCT ID:** NCT00171769
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2006-08
- **Final completion:** —
- **Target enrollment:** 200 (—)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171769, "Atrial Fibrillation Feasibility Certoparin Trial - AFFECT". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00171769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*